Erin Harris
Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Husk at besøge podcastens hjemmeside og støtte skaberen: www.buzzsprout.com
Forfatter
Erin Harris
Kategori
Podcastens hjemmeside
Seneste episode
19. nov. 2026
Hvor kan du lytte?
Podcasts i appen Replaio Radio Kommer snartPodcasts kommer snart til appen. Installer nu, og vær den første til at se en helt ny tilgang til podcasts
Episoder
Rethinking CGT Biotech Growth & Investment with Audrey Greenberg 10.04.2025 28:15
We love to hear from our listeners. Send us a message. On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures. They explore the...
Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita 27.03.2025 14:53
We love to hear from our listeners. Send us a message. In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved the...
Harnessing the Power of Cord Blood Tregs with Cellenkos' Dr. Simrit Parmar 13.03.2025 34:57
We love to hear from our listeners. Send us a message. In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases. Dr. Parmar shares the vision behind Cellenkos, the advantages of cord blood-derived Tregs over other so...
CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D. 27.02.2025 28:42
We love to hear from our listeners. Send us a message. Omkar Kawalekar, Ph. D., Senior Manager, NextGen Therapies Manufacturing & Supply Chain Lead, Deloitte Consulting joins Host Erin Harris to share his expert take on how distributed manufacturing models address capacity constraints and supply chain risks, the role of automation in reducing batch-to-batch variability, as well as the power of...
Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali 13.02.2025 35:38
We love to hear from our listeners. Send us a message. In this episode, Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insights on Tenaya's gene therapy platform, their in-house manufacturing capabilities, and the potent...
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D. 30.01.2025 26:49
We love to hear from our listeners. Send us a message. Helen Sabzevari, Ph. D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in developing effective gene therapies. Sabzevari also discusses Precigen's recent BLA submission...
The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan 16.01.2025 24:24
We love to hear from our listeners. Send us a message. Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-...
Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D. 02.01.2025 14:49
We love to hear from our listeners. Send us a message. Cell & Gene: The Podcast Host Erin Harris talks to Christopher Choi, Ph. D., MBA, SVP Industry Partnership, Director of GMP and Cell Manufacturing Facility, and Associate Professor of Oncology at Roswell Park Comprehensive Cancer Center about the Center's Buffalo, NY-based cell and gene therapy hub slated to open in early 2025. They c...
Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig 19.12.2024 21:08
We love to hear from our listeners. Send us a message. Cell & Gene: The Podcast Host Erin Harris talks to Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) about the biggest challenges in developing gene therapies for cardiovascular diseases, specifically congestive heart failure (CHF). They discuss AB-1002, the gene...
Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit 05.12.2024 31:14
We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rhakit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments. They cover the limitations of curren...
Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene 21.11.2024 21:39
We love to hear from our listeners. Send us a message. Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on site during 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Clinical Assessment (JCA) in Europe and its potential impact on cell and gene therapies, how globalizat...
Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams 07.11.2024 20:52
We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies, with a particular focus on the TECELRA trial. The trial led to the FDA approval of Tecelra, marking...
Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte 24.10.2024 25:26
We love to hear from our listeners. Send us a message. This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph. D., CEO of Kiji Therapeutics, President of ISCT, and Executive Committee Member of ARM about Kiji's clinical plan and why iPSC-MSC therapy for inflammator...
Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D. 10.10.2024 14:18
We love to hear from our listeners. Send us a message. Carsten Linnemann, Ph. D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk through key challenges and opportunities in developing TCR therapies targeting neoantigens as well as...
Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge 25.09.2024 22:00
We love to hear from our listeners. Send us a message. Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases like retinitis pigmentosa. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website...
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino 12.09.2024 28:06
We love to hear from our listeners. Send us a message. Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing...
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts 29.08.2024 25:13
We love to hear from our listeners. Send us a message. Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL remains a disease that is managed, it is...
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D. 15.08.2024 27:58
We love to hear from our listeners. Send us a message. Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also provides a regulatory outlook for CGT developers....
Identifying Drug Development Opportunities for DMD with CureDuchenne 01.08.2024 29:55
We love to hear from our listeners. Send us a message. Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene therapies for Duchenne muscular dystrophy (DMD). M...
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington 18.07.2024 21:01
We love to hear from our listeners. Send us a message. Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss why in vivo delivery continues to be a bottl...
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D. 04.07.2024 35:30
We love to hear from our listeners. Send us a message. KSQ Therapeutics' CSO, Micah Benson, Ph. D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9...
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft 20.06.2024 27:52
We love to hear from our listeners. Send us a message. Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and intensity of expression of therapeutic pr...
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko 06.06.2024 14:52
We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach. Subscribe to the podcast! Apple | Spotify | You...
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley 28.05.2024 25:21
We love to hear from our listeners. Send us a message. Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grilley talks to us about her role as CRO at ISCT and the global regulatory landscape for cell and gene th...
Dr. Bruce Levine on ISCT and the Future of CAR-T 23.05.2024 31:49
We love to hear from our listeners. Send us a message. In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more. He talks about his time and learnings as President Elect, President, and Immediate Past Presiden...
Lignende podcasts
Replaio er ikke podcastudgiver; programmernes navne, coverbilleder og lyd tilhører deres ophavsmænd og distribueres via offentlige RSS-feeds.